Altamira Therapeutics Ltd.

As of June 30, 2019, Altamira Therapeutics Ltd. carries a market capitalization of 3.62B, placing it among publicly traded companies globally. Its enterprise value stands at 3.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Altamira Therapeutics Ltd.'s next confirmed earnings release is scheduled for April 14, 2027.

As of June 30, 2019, Altamira Therapeutics Ltd. has 8,168.00 shares outstanding.

These figures are as of June 30, 2019.

As of June 30, 2019, Altamira Therapeutics Ltd. maintains a current ratio of 3.54, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2019.

Over the twelve months ended June 30, 2019, Altamira Therapeutics Ltd. recorded 176,895.67 in income tax expense.

As of the close on October 20, 2026, Altamira Therapeutics Ltd.'s stock has declined approximately 1.35% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.08.

These figures are as of June 30, 2019. Total book value stands at 9.39M, with working capital of 4.76M providing operational flexibility.

These figures cover the twelve months ended June 30, 2019.

Altamira Therapeutics Ltd.'s most recent stock split took place on December 13, 2023 with a 20:1 split ratio.